Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group ( (HK:2005) ) has shared an update.
SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of Arbidol Hydrochloride Tablets, a drug used to treat various viral infections including influenza and coronavirus-related illnesses. This approval marks a significant step in the company’s product development, potentially enhancing its market position and offering new treatment options for respiratory infections.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in the manufacture of both bulk drugs and finished products, with a market focus on treatments for viral infections.
YTD Price Performance: -6.47%
Technical Sentiment Signal: Buy
Current Market Cap: $1.2B
For a thorough assessment of 2005 stock, go to TipRanks’ Stock Analysis page.